Newron Pharmaceuticals (NWRN) - Seeing STARS

06:50 EDT 26 Mar 2020 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - Newron Pharmaceuticals: The statistical analysis plan for the pivotal STARS trial of sarizotan for symptomatic treatment of Rett syndrome should be FDA approved soon. This will allow data analysis, meaning that top-line data could be out by mid-2020. In FY19, Xadago (Parkinson’s disease) generated royalties of €4.7m plus a €2.3m Japanese milestone. A trial in dyskinesia is planned to expand the indication. Evenamide, a novel schizophrenia therapy, may start Phase III from Q420. Newron has cash (€39.2m) and loan facilities (€22.5m) to last through 2021. Our indicative value has been adjusted to CHF340m (CHF19.10/share), formerly CHF466m, taking into account sales, revised trial durations and start windows and debt.
ISIN: IT0004147952

Original Article: Newron Pharmaceuticals (NWRN) - Seeing STARS


More From BioPortfolio on "Newron Pharmaceuticals (NWRN) - Seeing STARS"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...